10 biotech consultants
Launch planning, partnering and asset choice are the main tracks in this group of biotech consultants: a 27-year Eli Lilly oncology commercial leader and Medivation's former XTANDI team leader on launches, former chief business officers of ASLAN Pharmaceuticals and Chimeric Therapeutics on deals, plus portfolio, clinical operations and fundraising advisers. They suit a small biotech choosing which asset to fund, when to partner or how to prepare a first launch.
Professionals to explore
Bob Marchesani
LinkedInExperience: President and Principal Consultant · Proventus Consulting LLC
Bob Marchesani spent 27 years in Senior Global Commercial Leadership Roles, Oncology at Eli Lilly and Company (1990 to 2017) and has been President and Principal Consultant at Proventus Consulting LLC since 2017. Marchesani advises biotech and pharma CEOs, primarily in oncology, on enterprise commercial strategy, launch readiness and value creation, and has been a Board Member at AVIPERO Bio since 2022.
Is this you? Claim your profile and get paid for calls.
Dr. Candice M. Hughes, PhD, MBA, RIMS-CRMP
LinkedInExperience: CEO, Founder, Biotechnology Pharmaceutical Consultant · Hughes BioPharma Advisers LLC Clinical Operations Consulting
Candice M. Hughes has been CEO and Founder of Hughes BioPharma Advisers LLC Clinical Operations Consulting since 2005, working on R&D operations, clinical trials, risk and audit, and brings board expertise in governance, risk management, compliance and audit. Hughes was Senior Management Consultant, R&D Operational Process, GXP SME at STEP-IN MANAGEMENT LTD (2020 to 2022) and Biopharma Life Sciences Adviser at NeoTelos Inc. (2024 to 2025).
Is this you? Claim your profile and get paid for calls.
Eliot Bourk
LinkedInExperience: Managing Director · Bourk BioAdvisors
Eliot Bourk has been Managing Director at Bourk BioAdvisors since 2025 and works in Global Commercial Strategy at Agios Pharmaceuticals since 2026, covering business development, commercial and portfolio strategy and program leadership. Bourk was VP, Head of Business Development at Adaptimmune (2024 to 2025) and Chief Business Officer & Head of External Innovation at Chimeric Therapeutics (2022 to 2024), a fit for licensing and partnering questions.
Is this you? Claim your profile and get paid for calls.
Paula Keebler
LinkedInExperience: Founder & Principal, Biopharma Commercial & Strategy Consulting Practice · Paula Keebler Advisory
Founder & Principal of Paula Keebler Advisory since 2018, Paula Keebler focuses on product strategy and launch readiness in rare disease and oncology. Keebler's roles include Marketing Director & XTANDI Team Leader at Medivation (2014 to 2017), Associate Director & Director, Global Business Analytics and Product Strategy at Onyx Pharmaceuticals, Inc., an Amgen subsidiary (2009 to 2014), and work at Mirum Pharmaceuticals, Inc. as a consultant through the advisory practice (2020 to 2022) and as Executive Director, Global Product Strategy (2025).
Is this you? Claim your profile and get paid for calls.
Philippe Barth
LinkedInExperience: Chief Executive Officer · PBA BIOTECH CONSULTING
Philippe Barth founded PBA BIOTECH CONSULTING in 2003 and was its Chief Executive Officer until 2019, advising more than 150 venture capital firms, life sciences companies and project holders on corporate strategy and raising capital. Based in Lyon, Barth is the person here for questions on structuring a biotech's financing strategy and approaching venture investors.
Is this you? Claim your profile and get paid for calls.
Richard Ogborne Ph.D., MBA.
LinkedInExperience: Independent Life Sciences Strategy Advisor · Independent Consultant
Which assets to prioritise, how to design development strategies and when to invest, partner or pivot are the questions Richard Ogborne Ph.D., MBA. works on as an Independent Life Sciences Strategy Advisor since 2026. Ogborne was Executive Director at Protagoras Group (2024 to 2026), Partner at Vintura (2020 to 2024) and Director, Life Science Strategy at Navigant (2017 to 2020).
Is this you? Claim your profile and get paid for calls.
Stefan Jehle
LinkedInExperience: Founder & Principal Consultant Biotech & Pharma Strategy, Commercial Excellence & B2B Sales · Swiss Consulting & Strategy
Based in Basel, Stefan Jehle has been Founder & Principal Consultant at Swiss Consulting & Strategy and External Advisor Commercial Strategy & Business Development at Genedata since March 2026, helping biotech and pharma companies with commercial strategy and sales pipelines. Jehle was Head of Sales (2019 to 2026) and Business Account Manager (2017 to 2026) at Genedata and Product Manager at Bruker BioSpin (2016 to 2017).
Is this you? Claim your profile and get paid for calls.
Stephen Doyle
LinkedInExperience: Founder and Consultant · Prestwick Advisory
Stephen Doyle founded Prestwick Advisory in 2026 and advises biotech and pharma companies on business development, partnership strategy and commercial execution, drawing on over 25 years of senior medical and commercial leadership across developed and emerging markets. Doyle was Chief Executive Officer and Managing Director at QBiotics Group Limited (2024 to 2025) and Chief Business Officer at ASLAN Pharmaceuticals (2019 to 2024).
Is this you? Claim your profile and get paid for calls.
William P. Gangi, MS, MBA
LinkedInExperience: Principal Consultant & Life Sciences Advisor · StratPlanX Biopharm Consulting, LLC
William P. Gangi, MS, MBA, provides fractional leadership and advisory services to small and emerging life sciences firms as Principal Consultant & Life Sciences Advisor at StratPlanX Biopharm Consulting, LLC since 2025. Gangi was Vice President, Portfolio & Program Management at Aura Biosciences (2021 to 2023), Sr. Director, Asset Lead (Program & Alliance Management) at Kiniksa Pharmaceuticals (2017 to 2021) and Director, Due Diligence Program Manager (Corporate Development) at Shire (2015 to 2017).
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
Launch planning fits Bob Marchesani (oncology), Paula Keebler (rare disease and oncology) or Sharon Rbeiz; partnering and business development fit Stephen Doyle or Eliot Bourk, and commercial excellence and B2B sales Stefan Jehle. For which asset to fund, ask Richard Ogborne or William P. Gangi; for clinical operations and audit readiness, Candice M. Hughes; and for corporate strategy and raising capital, Philippe Barth.
Questions to take into the conversation
- 01With two or three clinical assets and one financing runway, how should a small biotech decide which program to fund first?
- 02What commercial and market access work should start before a pivotal readout in oncology or rare disease?
- 03What do pharma business development teams expect to see before licensing an asset from a small biotech?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.